APAlfred M. Prince

Alfred M. Prince

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Alfred M. Prince has a total of 33 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Attempted therapeutic immunization in a chimpanzee chronic HBV carrier with a high viral load

    by Mohamed Tarek M. Shata, Wolfram Pfahler, Betsy Brotman, Dong‐Hun Lee, Nancy Tricoche, Krishna Murthy, Alfred M. Prince

    Background  We previously reported successful therapeutic immunization in a chimpanzee having a relatively low viral load, which was immunized with recombinant plasmid hepatitis B surface antigen (HBsAg) DNA and boosted with recombinant HBsAg encoding canarypox virus. In the present study, we attempted to confirm these findings in an animal with a high virus load.Methods and Results  We tested three immunization strategies successively over a 3‐year period. In the first of these, we administered four monthly injections of DNA encoding HBsAg + PreS2 + hepatitis B core antigen (HBcAg) + DNA encoding interleukin (IL)‐12, (given 3 days later), and boosted with canarypox expressing all of the above HBV genes 6 months after initial immunization. No reduction in viral load was observed. In the second trial, we administered lamivudine for 8 weeks, and then began monthly DNA‐based immunization with plasmids expressing the above viral genes; however, viral loads rebounded 1 week after termination of lamivudine therapy. In a third trial, we continued lamivudine therapy for 30 weeks and immunized with vaccinia virus expressing the above viral genes 18 and 23 weeks after the start of lamivudine therapy. Again viral loads rebounded shortly after cessation of lamivudine treatment. Analysis of cell‐mediated immune responses, and their avidity, revealed that DNA‐based immunization produced the strongest enhancement of high avidity T‐cell responses, while recombinant vaccinia immunization during lamivudine therapy enhanced low avidity responses only. The strongest low and high avidity responses were directed to the middle surface antigen.Conclusions  Three strategies for therapeutic immunization failed to control HBV viremia in a chronically infected chimpanzee with a high viral load.


  • Open Access

    Protection against Chronic Hepatitis C Virus Infection after Rechallenge with Homologous, but Not Heterologous, Genotypes in a Chimpanzee Model

    by Alfred M. Prince, Betsy Brotman, Dong‐Hun Lee, Wolfram Pfahler, Nancy Tricoche, Linda Andrus, Mohamed T. Shata

    An open question for hepatitis C virus (HCV) vaccine development is whether the various genotypes of this virus protect against the development of ch


  • Open Access

    Individual Donor Nucleic Acid Amplification Testing for Detection of West Nile Virus

    by Dong-Hun Lee, John Mathew, Wolfram Pfahler, Dongling Ma, Jay Valinsky, Alfred M. Prince, Linda Andrus

    We have developed an economical, high-throughput nucleic acid amplification test (NAT) for blood-borne viruses, suitable for use in the screening of plasma samples from individual blood donors. This assay system includes a semiautomated procedure, using 96-well glass fiber plates for the extraction of viral nucleic acids from plasma and “universal beacon” technology which permits the detection of all genotypes of highly variable viruses (e.g., human immunodeficiency virus and hepatitis C virus). In this detection system, two fluorescent- detection technologies were employed successfully in a single tube: molecular beacon for West Nile virus (WNV) detection using a 6-carboxyfluorescein fluorophore and TaqMan for internal control detection using a VIC fluorophore. To establish proof of concept, we focused on the development of a robust individual donor NAT for WNV. The assay showed no reactivity to 15 other viruses tested or to 420 blood donor samples from the WNV pre-epidemic season. No cross-contamination was observed on an alternating positive-/negative-well test. The sensitivity (limit of detection, 95%) of the assay for WNV is between 3.79 and 16.3 RNA copies/ml, depending on which material was used as a standard. The assay detected all positive blood donation samples identified by the Roche WNV NAT. The assay can be performed qualitatively for screening and quantitatively for confirmation.


  • Hepatitis C virus replication kinetics in chimpanzees with self‐limited and chronic infections

    by A. M. Prince, J.‐M. Pawlotsky, A. Soulier, L. Tobler, B. Brotman, W. Pfahler, D.‐H. Lee, Liping Li, M. T. Shata

    Summary. The availability of molecular beacon‐based, real time polymerase chain reaction (PCR) and a semi‐automated sample extraction procedure have made it possible for us to retrospectively examine HCV replication kinetics in HCV naive chimpanzees infected during the past 20 years. We compared these in 17 animals that developed chronic infection, and in 21 that developed self‐limited infection. No differences were found in infecting dose, or replication kinetics in the acute phase between these two types of infection. An unanticipated finding was the fact that 10 of 17 animals developing chronic infection partially controlled virus replication for 48 ± 48 weeks after typical acute phase viraemia, and prior to development of chronic infection. Twenty‐nine out of 30 (29/30) sera, which were negative by quantitative PCR during the downregulated period, were, however, positive by the more sensitive Genprobe isothermal transcription‐mediated amplification (TMA) assay. Thus, downregulation was not complete. Ten animals showing self‐limited infection showed complete resolution of viraemia by TMA assay. Quasispecies analysis revealed that in all, except one case, the virus reappearing after downregulation was essentially identical to that of the originally infecting virus.


  • Top Cited Papers

    Hepatitis B Virus Infection — Natural History and Clinical Consequences

    by Don Ganem, Alfred M. Prince

    This review article examines the structure and replication cycle of hepatitis B virus and discusses the natural history of primary infection, the mechanisms of clearance of the virus, and reasons for persistent infection. It concludes with a discussion of what we know about the virus and how it causes hepatitis and the implications for treatment.


  • Open Access

    Molecular cloning and characterization of onchocystatin, a cysteine proteinase inhibitor of Onchocerca volvulus.

    by S Lustigman, B Brotman, T Huima, A.M. Prince, J.H. McKerrow


    • 1 February 1992
      • Vol. 79  (3) , 826-31

    Solvent/detergent-treated plasma: a virus-inactivated substitute for fresh frozen plasma.

    by B Horowitz, R Bonomo, A M Prince, S N Chin, B Brotman, R W Shulman

    Fresh frozen plasma (FFP) is prepared in blood banks world-wide as a by-product of red blood cell concentrate preparation. Appropriate clinical use is for coagulation factor disorders where appropriate concentrates are unavailable and when multiple coagulation factor deficits occur such as in surgery. Viral safety depends on donor selection and screening; thus, there continues to be a small but defined risk of viral transmission comparable with that exhibited by whole blood. We have prepared a virus sterilized FFP (S/D-FFP) by treatment of FFP with 1% tri(n-butyl)phosphate (TNBP) and 1% Triton X-100 at 30 degrees C for 4 hours. Added reagents are removed by extraction with soybean oil and chromatography on insolubilized C18 resin. Treatment results in the rapid and complete inactivation of greater than or equal to 10(7.5) infectious doses (ID50) of vesicular stomatitis virus (VSV) and greater than or equal to 10(6.9) ID50 of sindbis virus (used as marker viruses), greater than or equal to 10(6.2) ID50 of human immunodeficiency virus (HIV), greater than or equal to 10(6) chimp infectious doses (CID50) of hepatitis B virus (HBV), and greater than or equal to 10(5) CID50 of hepatitis C virus (HCV). Immunization of rabbits with S/D-FFP and subsequent adsorption of elicited antibodies with untreated FFP confirmed the absence of neoimmungen formation. Coagulation factor content was comparable with that found in FFP. Based on these laboratory and animal studies, together with the extensive history of the successful use of S/D-treated coagulation factor concentrates, we conclude that replacement of FFP with S/D-FFP, prepared in a manufacturing facility, will result in improved virus safety and product uniformity with no loss of efficacy.


  • Hemodynamic Effects After Partial Exchange Transfusion with Pyridoxylated Polyhemoglobin in Chimpanzees

    by Gunther Lenz, Hermann Junger, Rinus Van Den Ende, Betsy Brotman, Alfred M. Prince

    Partial exchange transfusion with 8.5% pyridoxylated polyhemoglobin solution [PolyHb-PPa] was performed in five anesthetized spontaneously-breathing male chimpanzees weighing 22-30 kg. Mean exchange volume was 42.5 +/- 10.7 ml/kg BW (26.8-54.6 ml/kg), mean exchange rate 56.7 +/- 7.1% (48.2-67.4%). All animals survived long-term. The chimpanzee's hemodynamics remained stable for the 5 h observation period. Right and left ventricular filling pressures remained constant, mean arterial pressure and mean pulmonary arterial pressure increased by up to 40% after the exchange. Cardiac output remained unaffected by the partial exchange and stroke volume did not change substantially although oxygen capacity and oxygen transport capacity decreased by about a third. The failure of cardiac output to rise after partial exchange transfusion with PolyHb-PPa contrasts with results after isovolemic hemodilution using non-oxygen-carrying blood substitutes and is not adequately explained by the oxygen capacity of 8.5% PolyHb-PPa (9.3 ml O2/dl).


    • 1 January 1988
      • Vol. 21, 202-4

    [Inactivation of hepatitis non-A, non-B virus in intravenous immunoglobulins by beta-propiolactone].

    by H Dichtelmüller, W Stephan, A M Prince, B Brotman

    • 1 January 1984
      • No. 63,p. 355-72

    An affordable multideterminant plasma-derived hepatitis B virus vaccine.

    by A M Prince, J Vnek, B Brotman

    A new vaccine is reported which contains hepatitis B virus (HBV) e antigen (HBeAg) and pre-S determinants, in addition to highly purified HBV surface antigen (HBsAg). The rationale for this approach depends on the following data indicating that anti-HBe and antibody to the core antigen (anti-HBc), and antibody to pre-S determinants may play an active role in preventing HBV infection: (1) active immunization of chimpanzees with HBeAg(s) devoid of detectable HBsAg protected against subsequent challenge with HBV; (2) passive immunization of chimpanzees with an anti-HBe/anti-HBc intravenous immunoglobulin devoid of anti-HBs significantly delayed and appeared to attenuate HBV infection following subsequent challenge with HBV; (3) antibody to pre-S determinants appears to be able to neutralize infective HBV. The purification procedure used for the production of the New York Blood Center vaccine was designed to accomplish a high degree of purification with minimal use of complex equipment. This may facilitate eventual utilization of the vaccine on a mass scale for prevention of the HBV carrier state in high-prevalence regions of the world. The procedure uses polyethylene glycol (PEG) precipitations and hydroxylapatite adsorption steps, followed by only a single isopycnic separation in a zonal rotor, to achieve a vaccine which is substantially free of serum proteins and detectable HBV DNA yet contains HBsAg, HBeAg and pre-S determinants. The original vaccine was inactivated by Tween 80 and formalin. Four lots passed chimpanzee safety tests; two of these have been tested in clinical trials. Recently an improved vaccine has been developed in which two heat inactivation steps are used instead of formalin inactivation. This has resulted in further improvement in yields of antigenicity and immunogenicity, and provides an additional margin of safety.